เกล็ดเลือด และการใช้เกล็ดเลือด

Kuter DJ. Megakaryopoiesis and thrombopoiesis. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U,eds. Williams Hematology. 6th ed New York: McGraw- Hill, 2001: 1339-55.

Nichol JL, Hokom MM, Hornkohl A, Sheridan WP, Ohashi H, Kato T, Li YS, et al. Megakaryocyte growth and development factor. Analyses of in vitro effects on human megakaryopoicsis and endogenous serum levels during chemotherapy-induced thrombocytopenia. J Clin Invest 1995; 95: 2973-78.

Karker LA, Finch CA. Thrombokinetics in man. J Clin Invest 1969; 48: 963-74.

Aster RH. Pooling of platclets in the spleen: Role in the pathogenesis of Whypersplenic" thrombocytopenia. Clin Invest 1966; 45: 645-57.

Curtis BR, Edwards JT, Hessner MJ, Klein JP, Aster RH. Blood group A and B antigens are strongly expressed on platelets of some individuals. Blood 2000; 1574-80.

Kruskall, MS. The perils of platelet transfusions [editorial; comment]. N Engl J Med 1997; 337: 1914-45.

Szymanski IO, Patti K, Kliman A. Efficacy of the Latham blood processor to perform plateletpheresis. Transfusion 1973; 13: 405-11.

Apheresis: A become a platelet donor. American Red Cross. Available from http://www.redcross.org/services/biomed/0,1082,0_554_,00.html

Hogge DE, Thompson BW, Schiffer CA. Platelet storage for 7 days in second-generation blood bags. Transfusion 1986; 26: 131-5.

Schiffer CA, Lee EJ, Ness PM, Reilly J. Chical evaluation of platelet concentrates stored for one to five days. Blood 1986; 67: 1591-4.

Gaydos LA, Freidreich EJ, Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med 1962; 266: 905-9.

Slichter SJ, Harker LA. Thrombocytopenia: Mechanisms and management of defects in platelet production. Clin Haematol 1978; 7: 523-8.

Heckman KD, Weiner GJ, Davis CS, Strauss RG, Jones MP, Burns CP. Randomized study ofprophylactic plateletelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/ML versus 20,000/ML. J Clin Oncol 1997; 15: 1143-9.

Rcbulla P, Finazzi G, Marangoni F, Avvisati Gugliota L, Tognoni G, Barbui T, Mandelli F, Sirchia Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto: The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. N Engl J Med 1997; 337: 1870-5.

O'Connell BA, Lee EJ, Schiffer CA. The value of 10 minute post transfusion platelet counts. Transfusion 1988; 28: 66-7.

Callow CR, Swindell R. Randall W, Chopra R. The frequency ofbleeding complications in patients with haematological malignancy following the introduction of a stringent prophylactic platelet transfusion policy. Br Haematol 2002; 118: 677-82.

Schiffer CA, Anderson KC, Bennett CL, Bernstein S, Elting LS, Goldsmith M, Michael Goldstein M, et al. Platelet transfusion for patients with cancer: Clinical practice guidelines of the American society of clinical oncology. J Clin Oncol 2001; 19: 1519-38.

Sagmeister M, Oec L, Gmur J. A restrictive platelet transfusion policy allowing long-term support of outpatients with severe aplastic anemia. Blood 1999;93: 3124-6.

Slichter S. Relationship between platelet count and bleeding risk in thrombocytopenic patients Transfus Med Rev 2004; 18: 153-67.

Bishop JF,McGrath K, Wolf'MM, De Luise T, Holdsworth R, Yuen K, Veale M, et al. Clinical factors influencing the efficacy of pooled platelet transfusions.Blood 198; 71: 383-7.

Petz LD, Garatty G, Calhoun L, Clark BD, Terasaki PI, Gresens C, Gombein JA, et al. Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity. Transfusion 2000; 40: 1446-56.

Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao KJ, Kickler T, et al. Factors affecting postransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005; 105: 4106-14.

Yankee RA,Grumet FC, Rogentine GN. Platelet transfusion: The selection of compatible platelet donors for refractory patients by lymphocyte HL-A typing. N Engl J Med 1969; 281: 1208-12.

Pappalardo PA, Secord AR, Quitevis P, Haimowitz MD, Goldfinger D. Platelet transfusion refractoriness associated withHPA-1a (PI(A1))) alloantibody without coexistent HLA antibodies successfully treated with antigennegative platelet transfusions. Transfusion 2001; 41:984-7.

National Institutes of Health Consensus Conference. Platelet transfusion therapy. Transfus Med Rev 1987; 1: 195-200.

Norfolk DR, Ancliffe PJ, Contreras M, Hunt BJ, Machin SJ, Murphy WG. Consensus conference on platelet transfusion. Royal College of Physicians of Edinburgh, 27-28 November 1997. Br J Haematol 1998; 101: 609-17.

Murphy S. Preservation and clinical use ofelatelet. In: Beutler E, Lichman MA, Coller BS, Kipps TJ, Seligsohn U,eds. Williams Hematology. 6th ed.New York: McGraw- Hill, 2001. p1905-16.